Skip to main content

Indian Journal of Hematology and Blood Transfusion

Ausgabe 3/2022

Inhalt (26 Artikel)

Review Article

Reinduction of the Temporarily Deferred Donors for Laying the Foundation of Safe and Sustainable Blood Supplies: A Review in the Indian Context

Priyadarsini Jayachandran Arcot, Karan Kumar, Suchet Sachdev, Ratti Ram Sharma, Poonam Coshic

Open Access Original Article

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis

Donghua He, Fangshu Guan, Minli Hu, Gaofeng Zheng, Jingsong He, Xiaoyan Han, Yang Yang, Pan Hong, Gang Wang, Yi Zhao, Wenjun Wu, Zhen Cai

Original Article

Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients

Esra Terzi Demirsoy, Ozgür Mehtap, Elif Birtas Atesoglu, Pinar Tarkun, Ayfer Gedük, Necmi Eren, Abdullah Hacihanefioglu

Original Article

Programmed Cell Death Ligand 1 Expression Level and Prognostic Significance in Acute Myeloid Leukemia

Ayfer Geduk, Elif B. Atesoglu, Ozgur Mehtap, Esra T. Demirsoy, Meral U. Menguc, Pinar Tarkun, Abdullah Hacihanefioglu, Sibel Balcı

Original Article

Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry

R. Gupta, P. Gupta, K. Rahman, S. Biswas, D. Chandra, M. K. Singh, M. K. Sarkar, A. Gupta, S. Nityanand

Original Article

The Prognostic Significance of the BIN1 and CCND2 Gene in Adult Patients with Acute Myeloid Leukemia

Xinwen Zhang, Hao Xiong, Jialin Duan, Xiaomin Chen, Yang Liu, Chunlan Huang

Original Article

Gastric MALT Lymphoma: A 8-Year Experience

Maria Eduarda Couto, Isabel Oliveira, Nelson Domingues, Luísa Viterbo, Ângelo Martins, Ilídia Moreira, Ana Espírito Santo, Sérgio Chacim, Cláudia Moreira, Dulcineia Pereira, Rui Henrique, José Mariz

Original Article

Usefulness of Leucocyte Cell Population Data by Sysmex XN1000 Hematology Analyzer in Rapid Identification of Acute Leukemia

Shruti Mishra, Gaurav Chhabra, Somanath Padhi, Sonali Mohapatra, Ashutosh Panigrahi, Mukund Namdev Sable, Prabodha Kumar Das

Original Article

Radiotherapy in Adult Burkitt Lymphoma: A Retrospective Analysis in a Large University Center

Ricardo Ferrari Pereira, Geovanne Pedro Mauro, Carolina Trindade Mello Medici, Lucas Coelho Casimiro, Eduardo Weltman

Original Article

Splenectomy in İmmune Thrombocytopenia: A Retrospective Analysis of 25-Year Follow-up Data from a Tertiary Health Clinic

Serdar Ozkok, Isik Kaygusuz Atagunduz, Osman Kara, Aslihan Sezgin, Toluy Ozgumus, Fatma Gecgel, Tulin Firatli Tuglular, Tayfur Toptas

Original Article

Comprehensive Thrombophilia Evaluation in Cerebral Venous Thrombosis: A Single Center Cross Sectional Study

Rajiv Kumar, Pulikottil Wilson Vinny, Vishnu G. Nair, Rajesh Jakku

COVID-19 Original Article

Are Hematologic Patients Trojan Horse for COVID-19?

Emrah Kılıçaslan, Işıl Erdoğan Özünal, Tayfun Elibol, Erman Öztürk

Zur Zeit gratis COVID-19 Original Article

Donor’s Perspectives on Blood Donation During Covid-19 Pandemic

Parmatma Prasad Tripathi, Vijay Kumawat, Gopal Kumar Patidar

Zur Zeit gratis COVID-19 Original Article

SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India

Srinivasa Rao Chunchu, Ushasree Ravula, Vikram Kumar Gente, Srinivas Bacchu, S. Pandu Ranga Rao, Srujaleswari Mooli

Open Access Original Article

Targeted Sequencing Identifies the Genetic Variants Associated with High-altitude Polycythemia in the Tibetan Population

Zhiying Zhang, Lifeng Ma, Xiaowei Fan, Kun Wang, Lijun Liu, Yiduo Zhao, ZhiPeng Zhao, Han Zhang, Tian Liang, Wenxue Dong, Peng Cai, Yansong Li, Jing Li, Songhua Zhou, Longli Kang

Original Article

Anti-D Alloimmunization After RhD Positive Red Cell Transfusion to Selected RhD Negative Patients

Prashant Pandey, Divya Setya, Mukesh Kumar Singh

Short Communication

Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma

Jaikumar Patel, Akanksha Garg, Kinnari Patel, Kamlesh Shah, Sanket Shah, Rajan Yadav, Asha Anand, Harsha Panchal, Apurva Patel, Sonia Parikh, Sandip Shah

Short Communication

Predicting Significant Hyperbilirubinemia in ABO Incompatibility: Is Cord Direct Antiglobulin Test Useful?

Sphurti Chowdhary, Usha Devi, Sethuraman Giridhar

Short Communication

Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease

Derya Koyun, Güldane Cengiz Seval, Ekin Kırcalı, Sinem Civriz Bozdağ, Selami Koçak Toprak, Pervin Topçuoğlu, Muhit Özcan, Önder Arslan, Taner Demirer, Osman İlhan, Meral Beksaç, Günhan Gürman, Meltem Kurt Yüksel

Correspondence

Baricitinib: Two Birds with One Stone

Fen Saj, Smita Kayal, Biswajit Dubashi, Prasanth Ganesan

Correspondence

Risk of Transfusion-Transmitted Hepatitis E Virus: Correspondence

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Images

Bullous Sweet Syndrome

Marcial Álvarez-Salafranca, Pablo Villagrasa-Boli, Sara Martínez-Cisneros, Mar García-García

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.